All In Biotech

Drug Trial Radar · NCT00000885

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

A Phase II Study of the Prolongation of Virologic Success (ACTG 372A) and Options for Virologic Failure (ACTG B/C/D) in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Last checked: Nov 19, 2026Latest source record: Oct 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

440

Actual

Start

Not stated

Primary completion

Not stated

Study completion Jun 2003

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). To evaluate the safety and tolerability of these treatment arms. \[AS PER AMENDMENT 06/16/99: To compare the time to confirmed treatment failure, permanent discontinuation of treatment, or death between the treatment arms.\] \[AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable.\] Group B: To compare the proportion of patients who achieve plasma HIV-1 RNA concentrations below 500 copies/ml, as assessed by the standard Roche Amplicor assay at Week 16, or to compare the absolute changes in plasma HIV-1 RNA concentrations at Week 16 across the treatment arms: ABC or approved nucleoside analogs and nelfinavir (NFV) or placebo in combination with efavirenz (EFV) and adefovir dipivoxil. To compare the safety and tolerability of these treatment arms. Group C: To monitor plasma HIV-1 RNA trajectory over time and determine the time to a confirmed plasma HIV-1 RNA concentration above 2,000 copies/ml on 2 consecutive determinations for patients treated with ZDV or stavudine (d4T) plus 3TC and IDV. Group D: To evaluate plasma HIV-1 RNA responses at Weeks 16 and 48. To evaluate the safety and tolerability of the treatment arms: ABC, EFV, adefovir dipivoxil, and NFV. This study explores new treatment options for ACTG 320 enrollees (and, if needed, a limited number of non-ACTG 320 volunteers) who have been receiving ZDV (or d4T) plus 3TC and IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, nonsequential cohorts (Groups A, B, C, D), different approaches to evaluating virologic success, i.e., undetectable plasma HIV-1 RNA levels, and virologic failure, i.e., plasma HIV-1 RNA levels of 500 copies/ml or more \[AS PER AMENDMENT 12/27/01: 200 copies/ml or more\], are explored while maintaining long-term follow-up of ACTG 320 patients. \[AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable. This study will examine the question of whether intensification of therapy can prolong the virologic benefit in individuals whose plasma HIV-1 RNA concentrations have been below the limits of assay detection on ZDV (or d4T) plus 3TC plus IDV.\]

Conditions

  • HIV Infections

Interventions

  • Indinavir sulfateDrug

  • Abacavir sulfateDrug

  • Nelfinavir mesylateDrug

  • EfavirenzDrug

  • LevocarnitineDrug

  • Adefovir dipivoxilDrug

  • LamivudineDrug

  • StavudineDrug

  • ZidovudineDrug

  • DidanosineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

53 sites in 2 countries. Site status is shown where the registry gives one.

  • Univ of Alabama at Birmingham

    Birmingham, Alabama

  • Univ of Southern California / LA County USC Med Ctr

    Los Angeles, California

  • Stanford at Kaiser / Kaiser Permanente Med Ctr

    San Francisco, California

  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium

    San Jose, California

  • San Mateo AIDS Program / Stanford Univ

    Stanford, California

  • Stanford Univ Med Ctr

    Stanford, California

  • Harbor UCLA Med Ctr

    Torrance, California

  • Univ of Colorado Health Sciences Ctr

    Denver, Colorado

  • Georgetown Univ Hosp

    Washington D.C., District of Columbia

  • Howard Univ

    Washington D.C., District of Columbia

  • Univ of Miami School of Medicine

    Miami, Florida

  • Emory Univ

    Atlanta, Georgia

  • Queens Med Ctr

    Honolulu, Hawaii

  • Univ of Hawaii

    Honolulu, Hawaii

  • Northwestern Univ Med School

    Chicago, Illinois

  • Cook County Hosp

    Chicago, Illinois

  • Rush Presbyterian - Saint Luke's Med Ctr

    Chicago, Illinois

  • Louis A Weiss Memorial Hosp

    Chicago, Illinois

  • Indiana Univ Hosp

    Indianapolis, Indiana

  • Division of Inf Diseases/ Indiana Univ Hosp

    Indianapolis, Indiana

  • Methodist Hosp of Indiana / Life Care Clinic

    Indianapolis, Indiana

  • Univ of Iowa Hosp and Clinic

    Iowa City, Iowa

  • Tulane Univ School of Medicine

    New Orleans, Louisiana

  • Johns Hopkins Hosp

    Baltimore, Maryland

  • Harvard (Massachusetts Gen Hosp)

    Boston, Massachusetts

  • Boston Med Ctr

    Boston, Massachusetts

  • Beth Israel Deaconess - West Campus

    Boston, Massachusetts

  • Beth Israel Deaconess Med Ctr

    Boston, Massachusetts

  • Univ of Minnesota

    Minneapolis, Minnesota

  • St Louis Regional Hosp / St Louis Regional Med Ctr

    St Louis, Missouri

  • Univ of Nebraska Med Ctr

    Omaha, Nebraska

  • SUNY / Erie County Med Ctr at Buffalo

    Buffalo, New York

  • Beth Israel Med Ctr

    New York, New York

  • Bellevue Hosp / New York Univ Med Ctr

    New York, New York

  • Chelsea Ctr

    New York, New York

  • Cornell Univ Med Ctr

    New York, New York

  • St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr

    New York, New York

  • Mount Sinai Med Ctr

    New York, New York

  • Univ of Rochester Medical Center

    Rochester, New York

  • Univ of North Carolina

    Chapel Hill, North Carolina

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.